Jesus Mendiola-Precoma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jesus Mendiola-Precoma has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Rodríguez Cruz
Escuela de Bachilleres de la Universidad Autónoma de Querétaro (México)
2 shared publications - Laura Cristina Berumen
Posgrado en Ciencias Químico Biológicas, Facultad de Química, Universidad Autónoma de Querétaro, CP. 76010, Cerro de las campanas S/N, Querétaro, Qro., México, Mexico
2 shared publications - Antonio Romo-Mancillas
Posgrado en Ciencias Químico Biológicas, Facultad de Química, Universidad Autónoma de Querétaro, Querétaro, México
1 shared publication Guadalupe García-Alcocer
Laboratorio de Investigación Genética, Facultad de Química, Universidad Autónoma de Querétaro, Querétaro, Mexico
1 shared publication- Guadalupe García-Alcocer
Posgrado en Ciencias Químico-Biológicas, Faculty of Chemistry, Autonomous University of Queretaro (UAQ), Cerro de las Campanas S/N, Querétaro 76010, Mexico
1 shared publication Jesica Esther Escobar-Cabrera
Laboratorio de Investigación Genética, Facultad de Química, Universidad Autónoma de Querétaro, Querétaro, Mexico
1 shared publication
Latest Publications
- Open Access
- 5 September 2022
- Published by CEF. Centro de Estudios Financieros in Revista Tecnología, Ciencia y Educación
- No. 23,p. 69-94
Diagnóstico del uso e implementación de la realidad aumentada en la Escuela de Bachilleres de la Universidad Autónoma de Querétaro
Hoy en día, en la educación, la tecnología de realidad aumentada es una herramienta con gran potencial debido a que permite a los docentes y al alumnado (hombres y mujeres) abordar de una manera más dinámica el tema de estudio, de tal forma que el objetivo de la presente investigación abarca el diagnóstico de la comprensión y uso de la realidad aumentada en una muestra de la población institucional de la Escuela de Bachilleres de la Universidad Autónoma de Querétaro. Los resultados sugieren que se tiene un mínimo conocimiento respecto a la implementación y gestión de esta tecnología como parte de las estrategias de enseñanza-aprendizaje, motivo por el cual esta herramienta, actualmente, tiene un escaso uso en el proceso de enseñanza. Con respecto a lo anterior, se propone la creación de entornos de aprendizaje que integren la realidad aumentada para así aspirar a aumentar la comprensión de los temas de estudio.
- 5 September 2022
- Published by CEF. Centro de Estudios Financieros in Revista Tecnología, Ciencia y Educación
- No. 23,p. 69-94
Open AccessDiagnóstico del uso e implementación de la realidad aumentada en la Escuela de Bachilleres de la Universidad Autónoma de Querétaro
Hoy en día, en la educación, la tecnología de realidad aumentada es una herramienta con gran potencial debido a que permite a los docentes y al alumnado (hombres y mujeres) abordar de una manera más dinámica el tema de estudio, de tal forma que el objetivo de la presente investigación abarca el diagnóstico de la comprensión y uso de la realidad aumentada en una muestra de la población institucional de la Escuela de Bachilleres de la Universidad Autónoma de Querétaro. Los resultados sugieren que se tiene un mínimo conocimiento respecto a la implementación y gestión de esta tecnología como parte de las estrategias de enseñanza-aprendizaje, motivo por el cual esta herramienta, actualmente, tiene un escaso uso en el proceso de enseñanza. Con respecto a lo anterior, se propone la creación de entornos de aprendizaje que integren la realidad aumentada para así aspirar a aumentar la comprensión de los temas de estudio.
- Open Access
- 1 June 2020
- Published by Elsevier in IBRO Reports
- Vol. 8, 28-35
“Effect of valerenic acid on neuroinflammation in a MPTP-induced mouse model of Parkinson’s disease”
- 1 June 2020
- Published by Elsevier in IBRO Reports
- Vol. 8, 28-35
Open Access“Effect of valerenic acid on neuroinflammation in a MPTP-induced mouse model of Parkinson’s disease”
- Open Access
- 1 January 2016
- Published by Wiley in BioMed Research International
- Vol. 2016, 1-17
Therapies for Prevention and Treatment of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia associated with a progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the world in 2015, and this figure is estimated to double by 2050. This disease is characterized by blood-brain barrier disruption, oxidative stress, mitochondrial impairment, neuroinflammation, and hypometabolism; it is related to amyloid-βpeptide accumulation and tau hyperphosphorylation as well as a decrease in acetylcholine levels and a reduction of cerebral blood flow. Obesity is a major risk factor for AD, because it induces adipokine dysregulation, which consists of the release of the proinflammatory adipokines and decreased anti-inflammatory adipokines, among other processes. The pharmacological treatments for AD can be divided into two categories: symptomatic treatments such as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists and etiology-based treatments such as secretase inhibitors, amyloid binders, and tau therapies. Strategies for prevention of AD through nonpharmacological treatments are associated with lifestyle interventions such as exercise, mental challenges, and socialization as well as caloric restriction and a healthy diet. AD is an important health issue on which all people should be informed so that prevention strategies that minimize the risk of its development may be implemented.
- 1 January 2016
- Published by Wiley in BioMed Research International
- Vol. 2016, 1-17
Open AccessTherapies for Prevention and Treatment of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia associated with a progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the world in 2015, and this figure is estimated to double by 2050. This disease is characterized by blood-brain barrier disruption, oxidative stress, mitochondrial impairment, neuroinflammation, and hypometabolism; it is related to amyloid-βpeptide accumulation and tau hyperphosphorylation as well as a decrease in acetylcholine levels and a reduction of cerebral blood flow. Obesity is a major risk factor for AD, because it induces adipokine dysregulation, which consists of the release of the proinflammatory adipokines and decreased anti-inflammatory adipokines, among other processes. The pharmacological treatments for AD can be divided into two categories: symptomatic treatments such as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists and etiology-based treatments such as secretase inhibitors, amyloid binders, and tau therapies. Strategies for prevention of AD through nonpharmacological treatments are associated with lifestyle interventions such as exercise, mental challenges, and socialization as well as caloric restriction and a healthy diet. AD is an important health issue on which all people should be informed so that prevention strategies that minimize the risk of its development may be implemented.